一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:B cell phenotypes and antibody signatures associate with interpatient variation in the lung adenocarcinoma tumor microenvironment.
B cell phenotypes and antibody signatures associate with interpatient variation in the lung adenocarcinoma tumor microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现揭示了 TI 免疫景观中存在显著的个体间差异,并突出了 LUAD 肿瘤内独特的 B 细胞库和亚同种型特征。总之,这些数据表明 B 细胞组成和抗体亚同种型的使用可能有助于免疫微环境,并可为 LUAD 中更定制化的免疫治疗策略的开发提供信息。
非小细胞肺癌是全球癌症相关死亡的主要原因,其中肺腺癌(LUAD)是最常见的亚型。尽管早期疾病通常采用手术治疗,但晚期LUAD通常需要化疗、放疗和/或免疫治疗,主要聚焦于T细胞介导的反应。然而,治疗效果也受到肿瘤浸润(TI)B细胞的影响,其在LUAD中的作用仍不完全清楚。
我们对48例LUAD患者的配对肿瘤、癌旁肺组织和外周血样本使用44个标志物进行了飞行时间流式细胞术(CyTOF),以定义TI免疫景观。共鉴定出66个免疫细胞亚群,并根据TI细胞组成将患者分为四组。对29例患者的配对样本进行了IgM和IgG的适应性免疫受体库测序(AIRR-seq),以评估克隆扩增和亲和力成熟。此外,对18例患者的肿瘤样本进行了亚同种型分辨的AIRR-seq。
CyTOF分析揭示了四个具有不同TI免疫特征的患者组。AIRR-seq显示,与邻近肺组织和血液相比,肿瘤中的克隆扩增和亲和力成熟增加。观察到肿瘤特异性IGHV富集模式,但与患者分组无关。相反,克隆扩增在淋巴细胞比例较高的肿瘤中最大。亚同种型分辨分析显示,IGHG2和IGHG3在TI B细胞丰度低的患者肿瘤中富集,而IGHG4在TI B细胞浸润高的患者中富集,并与四个CyTOF定义的免疫亚群相关。
We performed cytometry by time of flight (CyTOF) using 44 markers on matched tumor, adjacent lung, and peripheral blood samples from 48 LUAD patients to define TI immune landscapes. 66 immune cell subsets were identified, and patients were stratified into four groups based on TI cell composition. Adaptive immune receptor repertoire sequencing (AIRR-seq) of IgM and IgG was conducted on matched samples from 29 patients to assess clonal expansion and affinity maturation. Subisotype-resolved AIRR-seq was additionally performed on tumor samples from 18 patients.
CyTOF analysis revealed four patient groups with distinct TI immune profiles. AIRR-seq demonstrated increased clonal expansion and affinity maturation in tumors compared to adjacent lung and blood. Tumor-specific IGHV enrichment patterns were observed but were not associated with patient group assignment. Instead, clonal expansion was greatest in tumors with higher lymphocyte proportions. Subisotype-resolved analysis showed enrichment of IGHG2 and IGHG3 in tumors from patients with low TI B cell abundance, whereas IGHG4 was enriched in patients with high TI B cell infiltration and correlated with four CyTOF-defined immune subsets. DISCUSSION: These findings reveal substantial inter-individual variation in TI immune landscapes and highlight distinct B cell repertoire and subisotype features within LUAD tumors. Together, these data suggest that B cell composition and antibody subisotype usage may contribute to immune contexture and could inform the development of more tailored immunotherapeutic strategies in LUAD.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。